Cell Therapeutics Shows Positive Phase II/III Data For Pixantrone At ASH Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans 2H 2008 NDA for aggressive non-Hodgkin’s lymphoma, CEO Bianco tells “The Pink Sheet” DAILY.
You may also be interested in...
CTI Launches Phase III Trial Of Pixantrone In Indolent NHL
Pixantrone provides improvement over standard care for patients with relapsed follicular disease, CEO Bianco tells “The Pink Sheet” DAILY.
Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition
Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”